TaiMed Biologics (ROCO:4147) ROCE % : -1.14% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TaiMed Biologics's annualized ROCE % for the quarter that ended in Mar. 2024 was -1.14%.

TaiMed Biologics ROCE % Historical Data

The historical data trend for TaiMed Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics ROCE % Chart

TaiMed Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-13.06

-3.97

-10.16

-6.36

-4.93

TaiMed Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-8.25	-4.77	-0.23	-6.31	-1.14

TaiMed Biologics ROCE % Calculation

TaiMed Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-179.997	/	( ( (4101.112 - 329.863)	+	(3893.922 - 361.172) )	/ 2 )
	=	-179.997	/	( (3771.249	+	3532.75)	/ 2 )
	=	-179.997	/	3651.9995
	=	-4.93 %

TaiMed Biologics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-49.34	/	( ( (3893.922 - 361.172)	+	(5488.923 - 328.158) )	/ 2 )
	=	-49.34	/	( ( 3532.75	+	5160.765 )	/ 2 )
	=	-49.34	/	4346.7575
	=	-1.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

TaiMed Biologics (ROCO:4147) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TaiMed Biologics ROCE % Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiMed Biologics (ROCO:4147) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492

Website

http://www.taimedbiologics.com

TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.

TaiMed Biologics (ROCO:4147) Headlines

No Headlines